Infoblock alpha
q-bio/biomolecules IB-arxiv-2604.09369-crossabsense-gdp-a1 measured

On the GDPa1 benchmark of 242 therapeutic IgGs, CrossAbSense improved 12–20% over established baselines on three of five developability assays.

Active Evidence state is recorded explicitly and may be revised by a later event.

Observed quantities

n_iggs 242 · n_assays 5 · n_improved_assays 3 · gain_pct_low 12 · gain_pct_high 20

01

Primary source

  1. arxiv · 2604.09369 · v1 · abstract
Title
Biologically-Grounded Multi-Encoder Architectures as Developability Oracles for Antibody Design
Authors
Simon J. Crouzet
Version
v1
Check
Support quote found word for word in the arXiv abstract v1, 2026-10-08
Supporting quote from the source
On the GDPa1 benchmark of 242 therapeutic IgGs, our oracles achieve notable improvements of 12--20\% over established baselines on three of five developability assays

02

Boundary of this block

No additional public limitation was recorded.

03

Connections

Outgoing

No outgoing public edges.

Incoming

No incoming public edges.